Bioptimus AI
Bioptimus / bioptimus.com
AI foundation model for biology and genomics that learns biological representations from multi-omics data, enabling drug discovery, disease mechanism research, and genomic variant interpretation.
Pricing
Free
Free plan
No
Category
Developer Tools
Platforms
2
Free plan
No
API access
Yes
Open source
No
Platforms
2
Advertisement
What is Bioptimus AI?
Bioptimus is a French AI company developing foundation models specifically for biology and genomics, with the goal of building a universal AI model for life sciences analogous to GPT-4 for language. The company was founded by bioinformatics and AI researchers and has attracted significant early investment and pharmaceutical partnerships.
H-optimus-0, Bioptimus's initial model, is a foundation model trained on digital pathology whole-slide images at scale, similar in approach to AlphaFold but applied to histopathology rather than protein structure. The model learns visual representations of biological tissue that can be fine-tuned for specific diagnostic tasks.
The genomics foundation model being developed aims to learn biological representations from multi-omics data — genomics, transcriptomics, proteomics — creating a universal biological encoder that can be applied to drug target identification, disease mechanism discovery, and genomic variant interpretation.
Bioptimus has attracted attention as one of the European AI companies at the frontier of biological AI, competing with US companies like Genentech AI, Recursion, and Isomorphic Labs (DeepMind spinout). The company's collaboration with French academic institutions and the European biotech ecosystem positions it as a significant player in the growing European life sciences AI space.
At its early stage, Bioptimus is primarily accessible through research collaborations and pharmaceutical partnerships rather than commercial API access.
How Bioptimus AI works
Bioptimus AI runs as deep learning model software built around image and data workflows. Users typically start with a prompt, upload, or connected data source, and the underlying model handles the heavy lifting before returning a result you can refine or export. It's available on web and api, with API access for teams that want to embed it into their own products.
What makes it worth shortlisting
The capabilities that matter most for teams evaluating Bioptimus AI.
H-optimus-0
Pathology foundation model trained on whole-slide images learning tissue representations for fine-tuning to specific cancer detection and diagnostic research tasks.
Multi-omics representation
Foundation model training approach learning unified biological representations from genomics, transcriptomics, and proteomics data for cross-modal biological understanding.
Fine-tuning for specific tasks
Pre-trained biological representations that can be fine-tuned on specific datasets for tasks including diagnostic classification, drug target identification, and variant interpretation.
Best use cases
Who should use it
Pros
- Frontier biological AI development with a clear vision for universal biological foundation models
- H-optimus-0 pathology model is publicly available for research evaluation
- French and European positioning for the growing European life sciences AI market
- Strong academic founding team and pharmaceutical partnership interest validate approach
Cons
- Very early stage — limited commercial availability and unproven at pharmaceutical deployment scale
- Foundation model for biology is a long-term research bet rather than near-term commercial product
- Clinical validation of model outputs is a significant ongoing requirement for pharmaceutical applications
Advertisement
Is it worth the price?
Research and pharmaceutical partner access. No public pricing. Contact for partnership information. Raised $35M+ in funding.
Model
Enterprise
Starting price
Free
Free trial
No
Tools like Bioptimus AI
Recursion (covered, rank 372) is more established in high-throughput biological AI. PathAI (covered, rank 371) is more established in pathology AI. AlphaFold (covered, rank 355) is the established protein AI benchmark. Isomorphic Labs applies DeepMind's biological AI to drug discovery.
Bioptimus AI vs Recursion Pharmaceuticals
A side-by-side look at the closest alternative in this category.
Bioptimus AI
Bioptimus
Recursion Pharmaceuticals
Recursion Pharmaceuticals
Research and pharmaceutical partner access. No public pricing. Contact for partnership information. Raised $35M+ in funding.
Pharmaceutical partnership programmes. No public pricing or individual access. Publicly traded on NASDAQ (RXRX).
Research data handling agreements. GDPR compliant (French company). Enterprise partnership data handling agreements.
Enterprise research data handling agreements. GDPR compliant. Publicly traded company (RXRX) with standard public company disclosures.
Review Bioptimus's data handling policy for research partnerships. Biological and patient data processed under applicable research ethics and data protection frameworks.
Recursion processes biological research data under enterprise partnership data handling agreements.
- Frontier biological AI development with a clear vision for universal biological foundation models
- H-optimus-0 pathology model is publicly available for research evaluation
- French and European positioning for the growing European life sciences AI market
- Strong academic founding team and pharmaceutical partnership interest validate approach
- Trillion-cell dataset scale is unmatched for AI biological discovery — the data moat is exceptional
- Automated lab platform generates new data continuously rather than relying only on historical datasets
- NVIDIA partnership provides access to BioNeMo biological foundation models for enhanced predictions
- Pharmaceutical partnerships with Roche, Bayer, and Sanofi validate platform credibility
- Very early stage — limited commercial availability and unproven at pharmaceutical deployment scale
- Foundation model for biology is a long-term research bet rather than near-term commercial product
- Clinical validation of model outputs is a significant ongoing requirement for pharmaceutical applications
- Drug discovery timelines are inherently long — AI acceleration is measured in years
- Clinical success probability remains uncertain across the entire drug discovery industry
- Publicly traded company (RXRX) — review financial performance and analyst coverage before partnership commitments
Technical & deployment info
Key facts about model providers, platforms, and team support.
Model Provider
Bioptimus
Models
H-optimus-0
Platforms
Web, API
Deployment
SaaS, Research partnership
Integrations
Pharmaceutical research systems, Pathology imaging systems, API
Team Collaboration
No
Launch Year
2024
Security & privacy
Compliance signals and data-handling notes as reported by the vendor.
Research data handling agreements. GDPR compliant (French company). Enterprise partnership data handling agreements.
Review Bioptimus's data handling policy for research partnerships. Biological and patient data processed under applicable research ethics and data protection frameworks.
What users are saying
Verified reviews from signed-in users, stored in the backend and averaged into this tool's rating.
Sign in to rate Bioptimus AI and leave a review.
No other reviews yet — be the first to share how this tool performs in practice.
Common questions about Bioptimus AI
Editorial Verdict
Should you use Bioptimus AI?
Bioptimus is a company to watch for pharmaceutical companies evaluating cutting-edge biological AI, particularly for pathology AI and genomics foundation models in the European research context.
Last verified July 24, 2026.